Ben Carpenter Joins Evercore as Senior Managing Director in the Healthcare Investment Banking Group

Key Terms

biopharma medical

Biopharma companies discover and develop medicines and treatments derived from biological sources—such as proteins, cells, or genetic material—rather than from purely synthetic chemicals. For investors, biopharma matters because successful products can deliver large, protected revenues but require long, costly development and strict regulatory approval, creating a higher-risk, potentially higher-reward profile; think of them as chefs transforming living ingredients into precision medicines.

m&a financial

M&A, short for mergers and acquisitions, involves one company combining with or purchasing another company to grow, streamline operations, or gain competitive advantages. For investors, M&A activity can signal potential for increased value, new opportunities, or changes in market dynamics, making it an important factor to watch in the business landscape.

NEW YORK--(BUSINESS WIRE)-- Evercore announced today that Ben Carpenter has joined the firm as a senior managing director in the healthcare investment banking group, where he will focus on the biopharma sector. He will be based in San Francisco.

“We are pleased to welcome Ben to Evercore,” said Naveen Nataraj, co-head of U.S. investment banking. “His extensive healthcare experience will further strengthen our franchise as we continue to invest in and expand our healthcare advisory platform.”

“We are excited to have Ben join the firm,” said Francois Maisonrouge, chairman of Evercore’s global healthcare group. “Biopharma is one of the most dynamic areas in global healthcare. Continuing to deepen our presence in this sector reinforces Evercore’s ability to advise clients across the full innovation life cycle.”

Mr. Carpenter said, “Evercore has built an exceptional team of senior biopharma bankers, and I am excited to join that partnership. As the sector continues to evolve amid regulatory complexity and rapid scientific innovation, I look forward to advising our clients as they navigate these dynamics and pursue their strategic objectives.”

Mr. Carpenter joins Evercore with more than 20 years of investment banking experience. Most recently, he served as global co-head of healthcare investment banking at J.P. Morgan, where he also previously held leadership roles, including co-head of North America M&A and co-head of healthcare M&A. Before that, he was global head of life sciences M&A at Citi. Mr. Carpenter began his career as an associate at J.P. Morgan.

Mr. Carpenter holds a bachelor’s from the University of Virginia and an MBA from the Stephen M. Ross School of Business at the University of Michigan.

About Evercore
Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic and financial significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital, delivers equity research and equity sales and agency trading execution, and provides wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. For more information, please visit www.evercore.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260302909840/en/

Business Contact:

Naveen Nataraj

Co-Head of U.S. Investment Banking

Communications@Evercore.com



Media Contact:

Jamie Easton

Head of Communications & External Affairs

Communications@Evercore.com



Investor Contact:

Katy Haber

Head of Investor Relations & ESG

InvestorRelations@Evercore.com

Source: Evercore